Crossmark

CCL17 blockade as a therapy for osteoarthritis pain and disease

Crossref DOI link: https://doi.org/10.1186/s13075-018-1560-9

Published Online: 2018-04-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Ming-Chin

Saleh, Reem

Achuthan, Adrian

Fleetwood, Andrew J.

Förster, Irmgard

Hamilton, John A.

Cook, Andrew D.
Funding

Funding for this research was provided by:

Arthritis Australia (1757679)

National Health and Medical Research Council (1043147)

National Health and Medical Research Council (1043147)

National Health and Medical Research Council (Senior Principal Research Fellowship)

Deutsche Forschungsgemeinschaft (IRTG 2168)
License Information

Text and Data Mining valid from 2018-04-05
More Information

Article History

Received: 6 January 2018

Accepted: 6 March 2018

First Online: 5 April 2018

Ethics approval

: Experiments were approved by The University of Melbourne Animal Ethics Committee.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.